Physician profile
Geeta Gupta
NPI 1538151378
$2,882.72
in general payments reported to CMS, 2019-2025
24 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $270 · 2021: $129 · 2022: $396 · 2023: $783 · 2024: $222 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $532.13 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $344.73 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $338.21 | 2019-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $326.63 | 2019-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $215.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $184.71 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $143.82 | 2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $133.79 | 2019-2023 | |
| Coloplast Corp | $87.50 | 2022 | |
| Lilly USA, LLC | $84.14 | 2019-2021 | |
| Scpharmaceuticals INC. | $68.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.16 | 2019-2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $56.58 | 2022 | |
| Amarin Pharma, INC. | $44.48 | 2019-2020 | |
| Sanofi Pasteur INC. | $40.82 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.83 | 2019-2020 | |
| Abbvie INC. | $34.43 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $32.18 | 2019 | |
| Melinta Therapeutics, LLC | $29.60 | 2019 | |
| Scilex Pharmaceuticals INC. | $29.45 | 2019 | |
| Shire North American Group INC | $17.84 | 2019 | |
| Merck Sharp & Dohme LLC | $17.25 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.